The story of Sildenafil presents a interesting case for stakeholders in the medicinal sector. While initially a tremendous success, generating vast sums, the exclusivity lapse and the subsequent arrival of generic https://adult742634.blogpayz.com/42051486/the-little-copyright-and-pharma-a-risky-investment